학술논문
IgA Nephropathy in a Patient Treated with Adalimumab
Document Type
Report
Source
Case Reports in Nephrology and Dialysis. May 2021, Vol. 11 Issue 2, p233, 8 p.
Subject
Language
English
Abstract
Author(s): Tonja Mertelj [a]; Natasa Smrekar [b]; Nika Kojc [c]; Jelka Lindic [d]; Damjan Kovac [d] Background Immunoglobulin A (IgA) nephropathy (IgAN) is the most common glomerulonephritis (GN) worldwide [1]. [...]
Immunoglobulin A (IgA) nephropathy (IgAN) is the most common glomerulonephritis worldwide, characterized by IgA deposits in the glomerular mesangium. It has a progressive nature and can eventually lead to end-stage kidney failure. It can occur as a potential side effect of treatment with tumor necrosis factor alpha antagonist that has been used for numerous chronic inflammatory conditions, such as Crohn's disease. In this study, the case of a 33-year-old man with renal dysfunction, nephrotic proteinuria, and erythrocyturia is described. He had had a history of Crohn's disease for 8 years and had been treated with adalimumab for the past 7 years. The diagnosis of IgAN was confirmed by kidney biopsy. After discontinuance of adalimumab and the induction of corticosteroid therapy, he made a remarkable recovery. Four years after the first presentation of IgAN and discontinuation of adalimumab, his renal function was normal with no proteinuria and only mild erythrocyturia. Keywords: IgA nephropathy, Adalimumab, Crohn's disease, Glucocorticoids, Vedolizumab
Immunoglobulin A (IgA) nephropathy (IgAN) is the most common glomerulonephritis worldwide, characterized by IgA deposits in the glomerular mesangium. It has a progressive nature and can eventually lead to end-stage kidney failure. It can occur as a potential side effect of treatment with tumor necrosis factor alpha antagonist that has been used for numerous chronic inflammatory conditions, such as Crohn's disease. In this study, the case of a 33-year-old man with renal dysfunction, nephrotic proteinuria, and erythrocyturia is described. He had had a history of Crohn's disease for 8 years and had been treated with adalimumab for the past 7 years. The diagnosis of IgAN was confirmed by kidney biopsy. After discontinuance of adalimumab and the induction of corticosteroid therapy, he made a remarkable recovery. Four years after the first presentation of IgAN and discontinuation of adalimumab, his renal function was normal with no proteinuria and only mild erythrocyturia. Keywords: IgA nephropathy, Adalimumab, Crohn's disease, Glucocorticoids, Vedolizumab